| Status | Awaiting development |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Further information | Awaiting development |
| Process | Cost Comparison Standard |
| ID number | 6404 |
Provisional Schedule
| Expected publication | 19 February 2025 |
Project Team
| Project lead | Greg O'Toole |
Email enquiries
- If you have any queries please email TATeam7@nice.org.uk
| External Assessment Group | Liverpool Reviews and Implementation Group, University of Liverpool |
Stakeholders
| Companies sponsors | AstraZeneca (durvalumab) |
| Others | Department of Health and Social Care |
| NHS England | |
| Patient carer groups | Roy Castle Lung Cancer Foundation |
| Professional groups | Association of Cancer Physicians |
| Association of Respiratory Nurse Specialists | |
| British Thoracic Oncology Group | |
| Cancer Research UK | |
| Royal College of Physicians | |
| Associated public health groups | None |
| Comparator companies | Roche Products (atezolizumab) (confidentiality agreement not signed, not participating) |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health – Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare Products Regulatory Agency | |
| Scottish Medicines Consortium | |
| Welsh Government | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | Institute of Cancer Research |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 15 July 2024 | Invitation to participate |
| 04 July 2024 | Please note that following completion of the scoping process and the NICE Medicines Optimisation Team briefing it has been confirmed that this appraisal will be routed to the cost comparison process. The appraisal will begin during mid-July 2024 when we will write to you about how you can get involved. |
| 16 February 2024 | Awaiting development |
For further information on our processes and methods, please see our CHTE processes and methods manual